Janux Therapeutics reports after the bell today with short sellers meaningfully pulling back, even as the analyst community has spent months slashing price targets.
The short interest story is the most notable shift in positioning. Bears have covered aggressively — short interest has dropped nearly 18% over the past month to roughly 10.6% of the float, down from around 13% in late June. The lending market confirms there is no squeeze pressure driving that exit: availability is exceptionally loose at 1,382%, meaning there are roughly fourteen shares available to borrow for every one currently lent out. Cost to borrow sits at a negligible 0.55%. This looks like a deliberate unwind, not a forced one.
Options positioning has moved in the opposite direction, turning more guarded into the print. The put/call ratio has climbed to 0.80, up from readings in the 0.58–0.66 range through early-to-mid July. While still only a third of a standard deviation above its 20-day average, the direction of travel is clear — investors have been adding downside protection steadily over the past three weeks. That's a meaningful contrast to the short-covering story: short sellers are less committed, but options traders are more defensive.
The analyst debate reflects the stock's difficult recent history. Targets have been cut repeatedly since the start of the year — Barclays downgraded to Underweight in April with a $14 target, UBS moved to Neutral in the same month. Truist assumed coverage in late June and immediately lowered its target from $80 to $26. The consensus mean price target of roughly $37 sits well above the current price of $16, but given the volume and direction of recent cuts, that spread reflects stale optimism more than genuine upside conviction. Bulls point to the $950 million cash balance, the de-risking from the JANX008 discontinuation, and the long runway provided by JANX013 and JANX014 in prostate cancer. Bears focus on the early-stage, undiversified pipeline, phase I risks for JANX011, and competition in the autoimmune TCE space from established players including Gilead. Past reactions to events have been modest — the June 2026 update saw the stock gain 3% on the day and 8% over the following week, while the May print fell roughly 3% on the day before stabilising. Neither reaction was particularly violent.
The earnings report today is therefore less a test of whether the cash runway is intact and more a question of whether clinical updates on the TRACTr and TRACIr platforms can give the bull case something concrete enough to arrest the year-long compression in analyst targets.
See the live data behind this article on ORTEX.
Open JANX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
